Nanobody based imaging and targeting of ECM in disease and development
Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
1. A composition, comprising
a nanobody which is specific for and binds directly to a diseased state extracellular matrix (ECM) epitope, wherein the diseased state ECM epitope is (i) an epitope in EIIIB domain of fibronectin, or (ii) tenascin C or an epitope of tenascin C, wherein the nanobody is conjugated to an active agent, and wherein the nanobody comprises a complementarity determining region (CDR)1, CDR2 and CDR3 comprising a) SEQ ID NO: 19, SEQ ID NO: 36, and SEQ ID NO: 53, respectively; b) SEQ ID NO: 25, SEQ ID NO: 42, and SEQ ID NO: 59, respectively; c) SEQ ID NO: 26, SEQ ID NO: 43, and SEQ ID NO: 60, respectively; or d) SEQ ID NO: 28, SEQ ID NO: 45, and SEQ ID NO: 62, respectively.
2. The composition of claim 1 , wherein the active agent is linked to N-terminus of the nanobody.
3. The composition of claim 1 , wherein the active agent is linked to C-terminus of the nanobody.
4. The composition of claim 1 , wherein the active agent is an imaging probe.
5. The composition of claim 4 , wherein the imaging probe is selected from the group consisting of: a fluorophore, an immuno-histochemical tracer, a PET tracer, an NIR probe, a SPECT probe, a magnetic particle imaging probe, and a radio-isotope.
6. The composition of claim 1 , wherein the active agent is selected from the group consisting of: a drug, a toxin, an siRNA, an shRNA, a cytokine, an ECM remodeling enzyme, a CAR-T cell, a radio-isotope, and a nanoparticle drugs, toxins, siRNAs, shRNAs, cytokines, ECM remodeling enzymes, CAR T cells, and radio isotopes for targeted therapies or can be incorporated into nanoparticles conjugated with the nanobodies for selective delivery.
7. The composition of claim 1 , wherein the nanobody specifically binds the diseased state ECM epitope with a binding affinity in a nM to sub-pM range, and wherein the binding affinity is measured by Biolayer Interferometry (BLI).
8. The composition of claim 1 , wherein the nanobody comprises a sequence set forth in any one of SEQ ID NOs: 1-4.
9. A composition, comprising
a peptide comprising a sequence set forth in any one of SEQ ID NOs: 1-4 or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier.
10. The composition of claim 9 , wherein the peptide is conjugated to an active agent.
11. The composition of claim 9 , wherein the peptide is a monoclonal antibody, a humanized antibody, a chimeric antibody, a human antibody, or an antigen-binding fragment thereof.
12. The composition of claim 9 , wherein the fragment thereof is a CDR and wherein the peptide comprises a CDR1, CDR2 and CDR3 comprising a sequence having at least 80% sequence identity to a) SEQ ID NO: 19, SEQ ID NO: 36, and SEQ ID NO: 53, respectively; b) SEQ ID NO: 25, SEQ ID NO: 42, and SEQ ID NO: 59, respectively; c) SEQ ID NO: 26, SEQ ID NO: 43, and SEQ ID NO: 60, respectively; or d) SEQ ID NO: 28, SEQ ID NO: 45, and SEQ ID NO: 62, respectively.
13. The composition of claim 9 , comprising a nanobody comprising a sequence set forth in any one of SEQ ID NOs: 1-4 or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier.
14. The composition of claim 1 , wherein the nanobody specifically binds the diseased state ECM epitope with a binding affinity in a sub-pM range.
15. The composition of claim 1 , wherein the nanobody specifically binds the diseased state ECM epitope with a binding affinity in a pM range.